Claims for Patent: 9,730,943

Summary for Patent: 9,730,943

Title:	Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines
Abstract:	The present invention relates to alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (I) in which R1, R2 and R3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. ##STR00001##
Inventor(s):	Scott; William Johnston (Guilford, CT), Mowes; Manfred (Berlin, DE), Liu; Ningshu (Berlin, DE), Monning; Ursula (Woltersdorf, DE), Bomer; Ulf (Glienicke, DE)
Assignee:	BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE)
Application Number:	13/885,038
Patent Claims:	1. A compound of formula (I): ##STR00067## wherein: R.sup.1 is --(CH.sub.2).sub.n--(CHR.sup.4)--(CH.sub.2).sub.m--N(R.sup.5)(R.sup.5); R.sup.2 is a heteroaryl of structure: ##STR00068## wherein: * indicates the point of attachment of said heteroaryl to the rest of the structure of formula (I); R.sup.3 is C.sub.1-C.sub.3-alkyl substituted with 1 R.sup.8 group; R.sup.4 is hydroxy; R.sup.5 and R.sup.5' are independently a hydrogen atom or a C.sub.1-C.sub.3-alkyl group; or R.sup.5 and R.sup.5' are taken together with the nitrogen atom to which they are bound to form a 5- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen and sulfur and which is optionally substituted with 1 or more R.sup.6' groups; each occurrence of R.sup.6 and R.sup.6' is independently a hydrogen atom or a methyl group; R.sup.8 is aryl; and n is an integer of 1 and m is an integer of 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof, or a mixture of any of the foregoing. 2. The compound according to claim 1, wherein: R.sup.1 is --(CH.sub.2).sub.n--(CHR.sup.4)--(CH.sub.2).sub.m--N(R.sup.5)(R.sup.5); R.sup.2 is a heteroaryl of structure: ##STR00069## wherein: * indicates the point of attachment of said heteroaryl to the rest of the structure of formula (I); R.sup.3 is C.sub.1-C.sub.3-alkyl substituted with 1 R.sup.8 group; R.sup.4 is hydroxy; R.sup.5 and R.sup.5' are taken together with the nitrogen atom to which they are bound, to form a 5- to 7-membered nitrogen containing heterocyclic ring containing one oxygen atom, which is optionally substituted with 1 or more R.sup.6' groups; each occurrence of R.sup.6 and R.sup.6' is independently a hydrogen atom or a methyl group; each occurrence of R.sup.8 is aryl; and n is an integer of 1 and m is an integer of 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof, or a mixture of any of the foregoing. 3. A compound selected from the group consisting of: N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-[2-(4-fluorophe- nyl)ethoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamid- e; N-{8-({(2R)-3-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)- -7-[2-(4-fluorophenyl)ethoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyr- idine-3-carboxamide; N-{7-[2-(4-Fluorophenyl)ethoxy]-8-[2-hydroxy-3-(morpholin-4-yl)propoxy]-2- ,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyridine-3-carboxamide; rel-2-amino-N-{8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxy-- 2-methylpropyl}oxy)-7-[2-(4-fluorophenyl)ethoxy]-2,3-dihydroimidazo[1,2-c]- quinazolin-5-yl}pyrimidine-5-carboxamide; and rel-N-{8-({(2R)-3-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-2-hydroxy-2-methyl- propyl}oxy)-7-[2-(4-fluorophenyl)ethoxy]-2,3-dihydroimidazo[1,2-c]quinazol- in-5-yl}pyridine-3-carboxamide, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a physiologically acceptable salt thereof. 4. A pharmaceutical composition comprising the compound of formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing, according to claim 1, and a pharmaceutically acceptable diluent or carrier. 5. A pharmaceutical combination comprising: one or more compounds of formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of any of the foregoing, according to claim 1; and one or more agents selected from: a taxane, Docetaxel, Paclitaxel, or Taxol; an epothilone, Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2'-deoxyadenosine; Thioguanine; an anti-androgen, Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum derivative, Cisplatin, or Carboplatin; Chlorambucil; Methotrexate; and Rituximab.

Details for Patent 9,730,943

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2030-11-11
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2030-11-11
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2030-11-11